Ensuring Patient Access to Critical Breakthrough Products Act of 2024

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349; Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act; transitional coverage for emerging technologies (TCET) proposal Site neutrality payment proposals under Medicare Medicare Physician Fee Schedule reform H.R.7623, Telehealth Modernization Act, all provisions Medicare pathway to reimbursement for FDA-cleared Algorithm-Based Health Care Services/AI S. 5349, Ensuring Patient Access to Critical Breakthrough Products Act of 2024, all provisions

Client expense: $470,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development

Client expense: $390,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE